Free shipping on all orders over $ 500

Tamoxifen Citrate (ICI 46474)

Cat. No. M2280
Tamoxifen Citrate (ICI 46474) Structure
Synonym:

ICI 46474; Istubal; Nolvadex

Size Price Availability Quantity
Free Sample (0.5-1 mg)  USD 0 In stock
10mM*1mL in DMSO USD 55  USD55 In stock
100mg USD 40  USD40 In stock
500mg USD 60  USD60 In stock
1g USD 80  USD80 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Tamoxifen Citrate (Nolvadex) is an estrogen receptor antagonist with an IC50 of 31 μM for the MCF-7 cells. In some tissues such as the endometrium, it behaves as an agonist, hence tamoxifen may be characterized as a mixed agonist/antagonist.

Chemical Information
Molecular Weight 563.64
Formula C26H29NO.C6H8O7
CAS Number 54965-24-1
Solubility (25°C) DMSO 50 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] Turgut Karaca, et al. Int J Surg. Effects of tamoxifen citrate on postoperative intra-abdominal adhesion in a rat model

[2] V Hug, et al. J Clin Oncol. Tamoxifen-citrate counteracts the antitumor effects of cytotoxic drugs in vitro

Related Estrogen Receptor Products
hFSH-β-(33-53) TFA

hFSH-β-(33-53) TFA, a thiol-containing peptide which corresponds to a second FSH receptor-binding domain, is a FSHR (follicle-stimulating hormone receptor) antagonist. hFSH-β-(33-53) TFA inhibits binding of FSH to receptor and is a partial agonist of estradiol synthesis in Sertoli cells.

Yp537

Yp537 is an estrogen receptor (ER) inhibitor that blocks dimerization of the human estrogen receptor.

Palazestrant

Palazestrant is a novel, orally active, estrogen receptor antagonist and selective estrogen receptor degrader. It can be used in studies related to ER+/HER2+ breast cancer.

Acolbifene hydrochloride

Acolbifene hydrochloride is an active metabolite of EM800 and an orally available, selective estrogen receptor modulator (SERM) that inhibits estradiol-induced ERα (IC50 = 2 nM) and ERβ (IC50 = 0.4 nM) transcriptional activity, has significant anti-estrogenic effects on the mammary gland and uterus, and has anticancer activity. possesses anticancer activity.

Acolbifene

Acolbifene is an active metabolite of EM800 and an orally active pure anti-estrogen and selective estrogen receptor (ER) antagonist that inhibits estradiol-induced ERα (IC50 = 2 nM) and ERβ (IC50 = 0.4 nM) transcriptional activity and has anticancer activity.

  Catalog
Abmole Inhibitor Catalog




Keywords: Tamoxifen Citrate (ICI 46474), ICI 46474; Istubal; Nolvadex supplier, Estrogen Receptor, inhibitors, activators


Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.